LundinA.A.P., AdlerA.J., FeinrothM.V., BerlyneG.M., FriedmanE.A.Maintenance hemodialysis; survival beyond the first decade.JAMA1980; 244: 38–42.
2.
RosaA.A., FrydD.S., KjellstrandC.M.Dialysis symptoms and stabilization in long-term dialysis. Practical application of the CUSUM plot.Arch Intern Med1980; 140(6): 804–7.
BlumbergA., NelpW.B., HergstromR.M., ScribnerB.H.Extracellular volume in patients with chronic renal disease treated for hypertension by sodium restriction.The Lancet1967; 69–71.
5.
SchultzeS., PiefkeS., MolzahnM.Blood pressure in terminal renal failure.Nephron1980; 25: 15–24.
6.
WeidmanP., MaxwellM.H., LupuA.N., MassryS.G.Plasma renin activity and blood pressure in terminal renal failure.N Engl J Med1971; 285: 757–62.
7.
Man in't veldA.J., SchichtI.M., DerkxF.H.M., de BruynJ.H., SchalekampMADH. Effects of an angiotensin - converting enzyme inhibitor (captopril) on blood pressure in anephric subjects.Brit Med J1980; 288–90.
8.
ShimamotoK., WatariI., MiyaharaM.A study of plasma vasopressin in patients undergoing chronic hemodialysis.J Clin Endocrin Metab1977; 45: 714–8.
9.
Fasanella D'AmoreT., WautersJ.P., WaeberB., NussbergerJ., BrunnerH.R.Response of plasma vasopressin to changes in extracellular volume and/or plasma osmolality in patients on maintenance hemodialysis.Clin Nephrol1985; 23: 299–302.
10.
RatgeD., AugustinR., WisserH.Catecholamines, renin, aldosterone and arterial pressure in patients on chronic hemodialysis treatment.Int J Artif Organs1983; 6: 255–60.
11.
BergströmJ.Neurohormones and cardiovascular stability in hemodialysis and hemofiltration. In: NoséY., ed. Progress in Artificial Organs.Cleveland, ISAO Press, 1986; 103–10.
KriqzekA.Dopamine-beta-hydroxylase activity and catecholamine levels in the plasma of patients with renal failure.Nephron1979; 24: 170–3.
14.
McGrathM.B.P., LedinghamJ.G.G., BenedictC.R.Catecholamines in periperal venous plasma in chronic hemodialysis.Clin Sci Mol Med1978; 55: 89–96.
15.
TextorS.C., GavrasH., TifftC.P., BernardD.B., IdelsonB., BrunnerH.R.Norepinephrin and renin activity in chronic renal failure.Hypertension1981; 3: 294–9.
16.
KershE.S., KronfieldS.J., UngerA., PopperR.W., CantonS., CohnK.Autonomic insufficiency in uremia as a cause of hemodialysis-induced hypotension.N Engl J Med1974; 290: 650–3.
17.
IzzoM.S., SternsR.H., FreemanR.B.Sympathetic system hyperactivity in maintenance hemodialysis patients.Trans Am Soc Artif Intern Organs1982; 28: 604–7.
18.
CampeseV.M., RomoffM.S., LevitanD., LaneK., MassryS.G.Mechanisms of autonomic nervous system dysfunction in uremia.Kidney Int1981; 20: 246–53.
19.
RascherW., TulassayT., LangR.E.Atrial natriuretic peptide in plasma of volume loaded children with chronic renal failure.LancetII1985; 303–5.
20.
AndersonJ.V., RaineA.E.G., ProudlerA., BloomS.R.Effect of hemodialysis on plasma concentrations of atrial natriuretic peptide in adult patients with chronic renal failure.J Endocrinol1986; 110(2): 193–6.
21.
TalartschikJ., EisenhauerT., VothE., SoldG., SchelerF.Ist der Plasma-ANP-Spiegel ein Index für die Volumen-expansione bei Dialyspatienten.Z Kardiol1988; Suppl 2: 72–7.
22.
TheodorssonE.Regulatory peptides in renal failure: effects and possible pathophysiological role.Int J Artif Organs(in press).
23.
Odar-CederlöfI., TheodorssonE., ErikssonC-G, KjellstrandC.M.Plasma concentrations of calcitonin gene-related peptide increase during haemodialysis: relation to blood pressure.J Int Med1989; 226: 177–82.
24.
AmaraS.G., JonasV., RosenfeldM.G., OngE.S., EvansR.M.Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products.Nature1982; 298: 204–44.
25.
StenberghP.H., HöppnerJ.W.M., ZandbergJ., LipsC.J.M., JanszH.S.A second human calcitonin/CGRP gene.BEBF Letters1985; 183: 403–7.
26.
BrainS.D., WilliamsT.J., TippingsJ.R., MorrisH.R., MacIntyreI.Calcitonin gene related peptide is a potent vasodilatator.Nature1985; 313: 54–6.
27.
GirgisS.J., MacDonaldD.W.R., StevensonJ.C.Calcitonin gene related peptide potent vasodilatator and major product of calcitonin gene.The Lancet1985; 14–6.
28.
ZaidiM., BreimerL.H., MacIntyreI.The biology of the peptides from the calcitonin genes.Q J Exp Physiol1987; 72: 378–416.
29.
MorrisH.R., ParicoM., EtienneT., TippinsJ., GirgisS.I., MacIntyreI.M.Isolation and characterization of human calcitonin gene related peptide.Nature1984; 308: 746–8.
30.
StevensonJ.C., MacDonaldD.W.R., WartrenR.C., BookerM.W., WhiteheadMl. Increased concentration of circulating calcitonin gene related peptide during normal human pregnancy.Br Med J1986; 293: 1329–30.
31.
VillarrealD., FreemanR., VerburgK., BrandsM.Effects of calcitonin gene-related-peptide on renal blood flow in the rat.Proc Soc Exp Biol Med1988; 188: 316–22.
32.
XuD., WangX., WangJ-P. Calcitonin gene-related peptide (CGRP) in normotensive and spontaneously hypertensive rats.Peptides1989; 10: 309–12.
33.
StruthersA.D., BrownM.J., BlachamJ.L., MorrisH.R., MacIntyreI., StevensonJ.C.The acute effect of human calcitonin gene related peptide in man.J Endocrinol1985; 104(suppl): 129.
34.
GennariC., FischerJ.A.Cardiovascular action of calcitonin gene related peptide in humans.Calcif Tissue Int1985; 37: 581–4.
35.
HvarfnerA., BergströmR., MörlinC., TheodorssonE., LjunghallS.The calcitonin gene-related peptide (CGRP) response to intravenous calcium is related to blood pressure.Acta Physiol Scand1988; 132: 439–40.
36.
UddmanR., EdvinssonL., EkbladE., HåkanssonR., SundlerF.Calcitonin gene-related peptide (CGRP), perivascular distribution and vasodilatory effects.Reg Peptides1986; 15: 1–23.
